Protalix BioTherapeutics, Inc. (PLX)
Largest Insider Buys in Sector
PLX Stock Price History Chart
PLX Stock Performance
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Insider Activity of Protalix BioTherapeutics, Inc.
Over the last 12 months, insiders at Protalix BioTherapeutics, Inc. have bought $90,484 and sold $0 worth of Protalix BioTherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protalix BioTherapeutics, Inc. have bought $125,891 and sold $2.09M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bashan Dror (PRESIDENT AND CEO) — $90,484.
The last purchase of 64,516 shares for transaction amount of $90,484 was made by Bashan Dror (PRESIDENT AND CEO) on 2023‑10‑19.
List of Insider Buy and Sell Transactions, Protalix BioTherapeutics, Inc.
| 2023-10-19 | Bashan Dror | PRESIDENT AND CEO | 64,516 0.0878% | $1.40 | $90,484 | -2.07% | ||
| 2023-01-03 | Schwartz Aharon | director | 110,000 0.1979% | $1.42 | $155,815 | +30.97% | ||
| 2022-04-11 | Bashan Dror | President and CEO | 68,000 0.1528% | $1.50 | $102,000 | -19.15% | ||
| 2021-06-03 | Sale | Dexcel Pharma Technologies Ltd. | 10 percent owner | 857,506 1.9156% | $2.25 | $1.93M | -48.20% | |
| 2021-06-02 | Sale | Dexcel Pharma Technologies Ltd. | 10 percent owner | 61,211 0.1389% | $2.56 | $156,553 | -53.63% | |
| 2020-04-07 | Schwartz Aharon | director | 64,000 0.1994% | $2.43 | $155,264 | +53.33% | ||
| 2017-05-16 | Manor Moshe | President & CEO | 50,000 0.0383% | $0.81 | $40,500 | -20.48% | ||
| 2016-12-02 | Sale | Camber Capital Management LLC | 10 percent owner | 2.5M 2.5199% | $0.32 | $792,000 | +145.16% | |
| 2015-12-14 | Maimon Yossi | Vice President & CFO | 10,000 0.01% | $0.78 | $7,800 | -2.56% | ||
| 2015-10-19 | Camber Capital Management LLC | 10 percent owner | 4M 4.0937% | $1.00 | $4M | -18.37% | ||
| 2014-08-13 | Sale | Bronfeld Zeev | 4.4M 4.4447% | $2.47 | $10.87M | -21.67% | ||
| 2014-08-13 | Sale | Bio-Cell Ltd | 10 percent owner | 4.4M 4.4447% | $2.47 | $10.87M | -21.67% | |
| 2013-08-15 | Sale | Akirov Alfred | director | 2,330 0.0025% | $5.07 | $11,813 | -14.98% | |
| 2013-08-14 | Sale | Akirov Alfred | director | 110,000 0.1193% | $5.05 | $555,750 | -14.78% | |
| 2013-03-12 | Sale | Akirov Alfred | director | 10,000 0.0108% | $5.70 | $57,000 | -12.63% | |
| 2013-03-11 | Sale | Akirov Alfred | director | 18,300 0.0198% | $5.72 | $104,737 | -12.63% | |
| 2013-03-08 | Sale | Akirov Alfred | director | 16,898 0.0182% | $5.86 | $99,068 | -14.94% | |
| 2013-03-07 | Sale | Akirov Alfred | director | 8,435 0.0092% | $5.72 | $48,233 | -12.17% | |
| 2013-03-06 | Sale | Akirov Alfred | director | 4,700 0.0051% | $5.69 | $26,737 | -11.71% | |
| 2012-05-02 | Sale | Shaaltiel Yoseph | Executive VP, R&D | 300,000 0.3334% | $7.13 | $2.14M | -20.83% |
Insider Historical Profitability
| Bashan Dror | PRESIDENT AND CEO | 132516 0.1816% | $1.23 | 2 | 0 | <0.0001% |
| Camber Capital Management LLC | 10 percent owner | 10775000 14.77% | $1.23 | 1 | 1 | <0.0001% |
| Bio-Cell Ltd | 10 percent owner | 10066319 13.7985% | $1.23 | 0 | 1 | |
| Bronfeld Zeev | 10066319 13.7985% | $1.23 | 0 | 1 | ||
| FROST PHILLIP MD ET AL | 10 percent owner | 7610167 10.4317% | $1.23 | 2 | 25 | +14.01% |
| Akirov Alfred | director | 4915383 6.7378% | $1.23 | 0 | 7 | |
| Dexcel Pharma Technologies Ltd. | 10 percent owner | 3637314 4.9859% | $1.23 | 0 | 2 | |
| Hurvitz Eli | director | 1514480 2.076% | $1.23 | 0 | 1 | |
| Shaaltiel Yoseph | Executive VP, R&D | 463754 0.6357% | $1.23 | 4 | 16 | <0.0001% |
| Schwartz Aharon | director | 174000 0.2385% | $1.23 | 2 | 0 | +42.15% |
| Manor Moshe | President & CEO | 50000 0.0685% | $1.23 | 1 | 0 | <0.0001% |
| Maimon Yossi | Vice President & CFO | 10000 0.0137% | $1.23 | 1 | 13 | <0.0001% |
| Bar-Shalev Amos | director | 1680 0.0023% | $1.23 | 1 | 0 | <0.0001% |
| Aviezer David | President & CEO | 0 0% | $1.23 | 0 | 11 | |
| Almon Einat Brill | SVP, Product Development | 0 0% | $1.23 | 0 | 12 |
Institutional Investor Ownership
| BlackRock | $4.17M | 4.51 | 3.31M | -4.26% | -$185,493.40 | <0.0001 | |
| State Street | $1.04M | 1.13 | 826,581 | 0% | +$0 | <0.0001 | |
| Renaissance Technologies | $1.04M | 1.13 | 824,700 | +23.9% | +$200,442.46 | <0.01 | |
| Geode Capital Management | $950,178.00 | 1.03 | 754,110 | +4.08% | +$37,214.08 | <0.0001 | |
| Gsa Capital Partners Llp | $622,000.00 | 0.67 | 493,571 | -9.31% | -$63,850.74 | 0.05 | |
| Northern Trust | $577,262.00 | 0.63 | 458,145 | -7.3% | -$45,475.86 | <0.0001 | |
| The Vanguard Group | $415,859.00 | 0.45 | 330,047 | +9.04% | +$34,474.84 | <0.0001 | |
| Nuveen | $342,462.00 | 0.37 | 271,795 | 0% | +$0 | <0.0001 | |
| Bridgeway Capital Management | $231,575.00 | 0.25 | 183,790 | -11.97% | -$31,499.95 | <0.01 | |
| BNY Mellon | $218,240.00 | 0.24 | 173,206 | -2.96% | -$6,664.15 | <0.0001 | |
| Morgan Stanley | $218,069.00 | 0.24 | 173,071 | -30.63% | -$96,300.34 | <0.0001 | |
| Virtu Financial Llc | $198,000.00 | 0.22 | 157,516 | New | +$198,000.00 | 0.02 | |
| Charles Schwab | $193,487.00 | 0.21 | 153,561 | 0% | +$0 | <0.0001 | |
| Bank of America | $144,345.00 | 0.16 | 114,560 | -43.6% | -$111,582.62 | <0.0001 | |
| Goldman Sachs | $116,454.00 | 0.13 | 92,424 | -11.54% | -$15,185.49 | <0.0001 | |
| TWO SIGMA SECURITIES LLC | $107,494.00 | 0.12 | 85,313 | +91.83% | +$51,456.96 | <0.01 | |
| Barclays | $105,000.00 | 0.11 | 82,434 | -34.42% | -$55,112.45 | <0.0001 | |
| RhumbLine Advisers | $96,325.00 | 0.1 | 76,455 | +3.76% | +$3,488.64 | <0.0001 | |
| Susquehanna International Group | $95,909.00 | 0.1 | 76,118 | -26.28% | -$34,186.43 | <0.0001 | |
| UBS | $85,625.00 | 0.09 | 67,956 | -9.05% | -$8,520.16 | <0.0001 | |
| HSBC | $58,817.00 | 0.06 | 46,680 | +16.51% | +$8,333.67 | <0.0001 | |
| New York State Common Retirement Fund | $58,000.00 | 0.06 | 45,655 | +1.23% | +$705.07 | <0.0001 | |
| Citadel Advisors LLC | $47,613.00 | 0.05 | 37,788 | New | +$47,613.00 | <0.0001 | |
| Franklin Templeton Investments | $42,270.00 | 0.05 | 33,548 | 0% | +$0 | <0.0001 | |
| American International Group | $41,984.00 | 0.05 | 33,321 | +1.05% | +$435.95 | <0.0001 | |
| JPMorgan Chase | $40,973.00 | 0.04 | 32,518 | -25.65% | -$14,132.27 | <0.0001 | |
| Jane Street Capital | $36,440.00 | 0.04 | 28,921 | +0.33% | +$120.96 | <0.0001 | |
| Voya Investment Management LLC | $34,049.00 | 0.04 | 27,023 | -7.66% | -$2,824.92 | <0.0001 | |
| Capital Performance Advisors Llp | $33,085.00 | 0.04 | 26,258 | +1.09% | +$356.58 | 0.03 | |
| Invesco | $32,644.00 | 0.04 | 25,908 | -3.63% | -$1,229.76 | <0.0001 | |
| Verition Fund Management Llc | $29,566.00 | 0.03 | 23,465 | New | +$29,566.00 | <0.0001 | |
| Wells Fargo | $29,445.00 | 0.03 | 23,369 | +17.25% | +$4,333.15 | <0.0001 | |
| AllianceBernstein | $29,484.00 | 0.03 | 23,400 | 0% | +$0 | <0.0001 | |
| SG Americas Securities, LLC | $27,000.00 | 0.03 | 21,467 | -37.97% | -$16,525.50 | <0.0001 | |
| Aptus Capital Advisors | $24,722.00 | 0.03 | 19,621 | +5.93% | +$1,384.71 | <0.01 | |
| Squarepoint Ops LLC | $22,447.00 | 0.02 | 17,815 | New | +$22,447.00 | <0.0001 | |
| T. Rowe Price | $21,000.00 | 0.02 | 15,982 | 0% | +$0 | <0.0001 | |
| Kestra Advisory Services LLC | $20,160.00 | 0.02 | 16,000 | +39.13% | +$5,670.00 | <0.0001 | |
| Lido Advisors, LLC | $19,598.00 | 0.02 | 15,554 | 0% | +$0 | <0.0001 | |
| Citigroup | $16,041.00 | 0.02 | 12,731 | +10.22% | +$1,486.79 | <0.0001 | |
| ProShares | $15,306.00 | 0.02 | 12,147 | +10.64% | +$1,471.76 | <0.0001 | |
| Altshuler Shaham Ltd | $15,299.00 | 0.02 | 12,142 | 0% | +$0 | <0.01 | |
| Harbour Investment Management LLC | $12,726.00 | 0.01 | 10,100 | 0% | +$0 | 0.01 | |
| Millennium Management LLC | $13,210.00 | 0.01 | 10,484 | New | +$13,210.00 | <0.0001 | |
| CalSTRS | $8,564.00 | 0.01 | 6,797 | -37.75% | -$5,193.59 | <0.0001 | |
| National Bank Of Canada Fi | $6,649.00 | 0.01 | 6,100 | 0% | +$0 | <0.0001 | |
| Legal & General | $6,752.00 | 0.01 | 5,359 | 0% | +$0 | <0.0001 | |
| Ameritas Investment Partners Inc | $5,844.00 | 0.01 | 4,638 | 0% | +$0 | <0.0001 | |
| Truvestments Capital Llc | $4,889.00 | 0.01 | 3,880 | 0% | +$0 | <0.01 | |
| Tower Research Capital | $4,905.00 | 0.01 | 3,893 | -67.37% | -$10,128.77 | <0.0001 |